2.80Open3.40Pre Close5 Volume339 Open Interest15.00Strike Price1.40KTurnover48.81%IV1.71%PremiumDec 20, 2024Expiry Date2.50Intrinsic Value100Multiplier19DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type0.9275Delta0.0706Gamma6.73Leverage Ratio-0.0086Theta0.0071Rho6.24Eff Leverage0.0055Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet